{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:06:44Z","timestamp":1781712404266,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.lungcan.2021.07.021","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T11:42:30Z","timestamp":1627990950000},"page":"59-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Antiphospholipid syndrome-induced ischemic stroke following pembrolizumab: Case report and systematic review"],"prefix":"10.1016","volume":"160","author":[{"given":"Vito","family":"Tota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Dagonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Wery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Binet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Durieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose-Antonio","family":"Elosegi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6026-2585","authenticated-orcid":false,"given":"St\u00e9phane","family":"Holbrechts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl_4","key":"10.1016\/j.lungcan.2021.07.021_b0005","first-page":"S1142","article-title":"KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) \u226550%","volume":"31","author":"Brahmer","year":"2020","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.lungcan.2021.07.021_b0010","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2021.07.021_b0015","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1038\/s41467-019-13120-6","article-title":"Stroke among cancer patients","volume":"10","author":"Zaorsky","year":"2019","journal-title":"Nat Commun."},{"key":"10.1016\/j.lungcan.2021.07.021_b0020","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2019.4669","article-title":"Cancer-associated stroke: pathophysiology, detection and management (Review)","author":"Dardiotis","year":"2019","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2021.07.021_b0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.lungcan.2021.07.021_b0030","article-title":"Thrombotic thrombocytopenic purpura induced by immune checkpoint inhibitiors: a case report and review of the literature","volume":"12","author":"Ali","year":"2020","journal-title":"Cureus."},{"issue":"3","key":"10.1016\/j.lungcan.2021.07.021_b0035","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","article-title":"American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association\/American Stroke Association","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.lungcan.2021.07.021_b0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/CMR.0000000000000335","article-title":"Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy","volume":"27","author":"Gupta","year":"2017","journal-title":"Melanoma Res."},{"issue":"11","key":"10.1016\/j.lungcan.2021.07.021_b0045","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamadermatol.2018.2770","article-title":"Antiphospholipid syndrome following pembrolizumab treatment of stage IIIB unresectable melanoma","volume":"154","author":"Sanchez","year":"2018","journal-title":"JAMA Dermatol."},{"issue":"2018","key":"10.1016\/j.lungcan.2021.07.021_b0050","first-page":"3106852","article-title":"APA induced by nivolumab","volume":"11","author":"Aburahma","year":"2018","journal-title":"Case Rep. Hematol."},{"key":"10.1016\/j.lungcan.2021.07.021_b0055","article-title":"Severe mesenteric ischemia with multiple organ failure in a patient previously treated with a humanized monoclonal antibody against programmed death receptor-1 (pembrolizumab), a case of pembrolizumab associated catastrophic antiphospholipid syndrome?","volume":"8","author":"Mintjens-Jager","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.lungcan.2021.07.021_b0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.lungcan.2017.01.016","article-title":"Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 2: Hematologic, cutaneous and vascular syndromes","volume":"106","author":"Holbrechts","year":"2017","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2021.07.021_b0065","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Longo","year":"2018","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.lungcan.2021.07.021_b0070","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.lungcan.2017.01.015","article-title":"Autoimmune paraneoplastic syndromes associated to lung cancer: a systematic review of the literature","volume":"106","author":"Durieux","year":"2017","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2021.07.021_b0075","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.cllc.2020.06.010","article-title":"Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression \u226550% and their relationship with clinical outcomes","volume":"21","author":"Cortellini","year":"2020","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2021.07.021_b0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.15403\/jgld.2014.1121.amb","article-title":"Autoimmune liver diseases and APAs positivity: a meta-analysis of literature studies","volume":"24","author":"Ambrosino","year":"2015","journal-title":"J. Gastrointestin. Liver Dis."},{"issue":"17","key":"10.1016\/j.lungcan.2021.07.021_b0085","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2021.07.021_b0090","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3390\/biomedicines8110508","article-title":"Management of antiphospholipid syndrome","volume":"8","author":"Ghembaza","year":"2020","journal-title":"Biomedicines"},{"issue":"22","key":"10.1016\/j.lungcan.2021.07.021_b0095","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood.V128.22.1180.1180","article-title":"Low- molecular weight heparins (LMWH) versus vitamin K antagonists (VKAs) in the treatment and secondary prevention of cancer-associated venous thromboembolism (VTE): a systematic review and meta-analysis of randomized controlled trials (RCTs)","volume":"128","author":"Thein","year":"2016","journal-title":"Blood"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221004876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221004876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:54:01Z","timestamp":1759236841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500221004876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":19,"alternative-id":["S0169500221004876"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.07.021","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiphospholipid syndrome-induced ischemic stroke following pembrolizumab: Case report and systematic review","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}